

STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 1999 KANSAS

LIST OF TABLES

OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

FOR ALL MEDICAID BENEFICIARIES

TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE 3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE 5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE 7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE 8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE 9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NF RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE 10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NF RESIDENTS, BY TOP 10 DRUG GROUP

APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY

APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS

FOR DUAL ELIGIBLE BENEFICIARIES

TABLE 11. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE 12. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE 13. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE 14. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE 15. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE 16-16D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE 17. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE 18. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NF RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY

APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS

TABLE 11

CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY^{a,b}
 DUAL ELIGIBLE BENEFICIARIES, KANSAS, 1999

Beneficiary Characteristics	No. of Benes						No. of Bene Mos					
	All	Aged	Disabled	Adults	Children	Other/ Unknown	All	Aged	Disabled	Adults	Children	Other/ Unknown
All	44,680	25,207	19,316	116	41	0	430,860	230,189	199,413	880	378	0
Age												
5 and younger	4	0	4	0	0	0	38	0	38	0	0	0
6-14	4	0	2	0	2	0	32	0	24	0	8	0
15-20	92	2	69	1	20	0	964	19	759	5	181	0
21-44	8,425	1	8,311	94	19	0	87,105	3	86,210	703	189	0
45-64	8,834	3	8,811	20	0	0	89,751	36	89,555	160	0	0
65-74	8,379	6,535	1,843	1	0	0	81,675	61,743	19,920	12	0	0
75-84	9,158	8,931	227	0	0	0	84,885	82,477	2,408	0	0	0
85 and older	9,784	9,735	49	0	0	0	86,410	85,911	499	0	0	0
Unknown	0	0	0	0	0	0	0	0	0	0	0	0
Gender												
Female	29,488	19,048	10,345	76	19	0	285,607	176,783	108,057	592	175	0
Male	15,192	6,159	8,971	40	22	0	145,253	53,406	91,356	288	203	0
Unknown	0	0	0	0	0	0	0	0	0	0	0	0
Race												
White	37,409	21,779	15,506	87	37	0	357,876	196,912	159,937	688	339	0
African American	4,862	2,034	2,806	20	2	0	49,029	19,647	29,236	131	15	0
Other/unknown	2,409	1,394	1,004	9	2	0	23,955	13,630	10,240	61	24	0
Use of Nursing Facilities												
All year	10,187	9,360	827	0	0	0	95,594	86,903	8,691	0	0	0
Part year	4,514	4,052	462	0	0	0	37,193	32,707	4,486	0	0	0
None	29,979	11,795	18,027	116	41	0	298,073	110,579	186,236	880	378	0
Maintenance Assistance Status												
Cash	14,620	4,652	9,908	59	1	0	155,266	48,845	105,972	447	2	0
Medically needy	26,883	19,602	7,246	2	33	0	244,630	172,890	71,401	24	315	0
Poverty-related	2,073	802	1,239	30	2	0	19,365	7,176	11,973	202	14	0
Other/unknown	1,104	151	923	25	5	0	11,599	1,278	10,067	207	47	0
Dual Medicare Status^c												
Full dual, all year	41,123	23,696	17,281	108	38	0	395,752	215,666	178,955	789	342	0
Full dual, part year	3,557	1,511	2,035	8	3	0	35,108	14,523	20,458	91	36	0
Managed Care Status												
FFS all year	38,815	21,294	17,379	104	38	0	396,931	207,995	187,748	824	364	0
FFS part year, with Rx claims	5,180	3,576	1,592	10	2	0	30,323	20,507	9,761	43	12	0
FFS part year, no Rx claims	685	337	345	2	1	0	3,606	1,687	1,904	13	2	0

Source: Data for this table are from the MAX 1999 file for Kansas, released by CMS in 1/2004. This table was produced on 06/25/2004.

a. Table 11 includes the beneficiaries represented by Cells G of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

Table 11

Dual Eligible Beneficiaries

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. The "Full dual, all year" group contains beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefits during all months of Medicaid enrollment in 1999. The "Full dual, part year" group contains beneficiaries who had such benefits for some, but not all, months of their enrollment. Refer to footnote g of Table 1 for more information about how we determined dual eligibility status.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE 12

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BENEFICIARY CHARACTERISTIC^{a,b}
DUAL ELIGIBLE BENEFICIARIES, KANSAS, 1999

Beneficiary Characteristics	% with at Least One Rx	Mean No. of Rx	Mean Rx \$	\$ per Rx	Mean \$, All Services	Rx \$ as % of All Services	Mean OTC Drug \$ ^c	No. of Benes
All	85.5 %	40.5	\$1,837	\$45	\$13,233	13.9 %	\$78	44,680
Age								
5 and younger	100.0	55.3	1,693	31	32,038	5.3	275	4
6-14	50.0	34.5	4,304	125	13,739	31.3	22	4
15-20	82.6	28.1	2,108	75	16,908	12.5	57	92
21-44	78.8	27.1	1,881	69	13,933	13.5	40	8,425
45-64	81.6	41.9	2,288	55	14,226	16.1	91	8,834
65-74	82.6	41.4	1,771	43	9,450	18.7	96	8,379
75-84	88.9	45.5	1,753	39	12,222	14.3	87	9,158
85 and older	94.0	45.4	1,521	34	15,880	9.6	76	9,784
Unknown	0.0	0.0	0	0	0	0.0	0	0
Basis of Eligibility								
Aged	88.7	44.7	1,676	38	13,136	12.8	84	25,207
Disabled	81.3	35.3	2,053	58	13,400	15.3	70	19,316
Adults	73.3	18.4	852	46	2,733	31.2	70	116
Children	65.9	21.4	1,343	63	24,444	5.5	105	41
Unknown	0.0	0.0	0	0	0	0.0	0	0
Gender								
Female	89.2	45.3	1,915	42	12,987	14.7	90	29,488
Male	78.1	31.3	1,684	54	13,711	12.3	55	15,192
Unknown	0.0	0.0	0	0	0	0.0	0	0
Race								
White	86.4	42.8	1,930	45	13,992	13.8	79	37,409
African American	80.6	30.2	1,431	47	10,426	13.7	82	4,862
Other/unknown	80.5	25.4	1,211	48	7,111	17.0	63	2,409
Use of Nursing Facilities								
Entire year	97.2	58.0	2,214	38	21,603	10.2	99	10,187
Part year	96.9	51.1	1,938	38	14,502	13.4	85	4,514
None	79.8	33.0	1,693	51	10,198	16.6	70	29,979
Maintenance Assistance Status								
Cash	88.1	34.9	1,760	50	8,739	20.1	77	14,620
Medically needy	86.7	46.3	1,978	43	16,635	11.9	85	26,883
Poverty related	50.8	11.5	652	57	1,833	35.6	24	2,073
Other/unknown	83.9	29.4	1,629	55	11,316	14.4	43	1,104

Source: Data for this table are from the MAX 1999 file for Kansas, released by CMS in 1/2004. This table was produced on 06/25/2004.

Table 12

Dual Eligible Beneficiaries

a. Table 12 includes beneficiaries represented by Cell G of Table 1.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Information about OTC drugs appears in this column only. OTC drugs are not part of the reimbursement amount for prescription drugs.

Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE 13
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b}
 DUAL ELIGIBLE BENEFICIARIES, KANSAS, 1999

Beneficiary Characteristics	Mean No. of Rx	Mean Rx \$	Rx \$ as % of All Services	No. of Rx, % with:					Mean \$, All Services	Benes	Bene Mos	
				None	More than 0, but 1 or Less	More than 1, but 2 or Less	More than 2, but 5 or Less	More than 5, but 10 or Less				More than 10
All	4.2	\$190	13.9 %	14.5 %	17.2 %	10.6 %	26.9 %	21.9 %	8.8 %	\$1,372	44,680	430,860
Age												
5 and younger	5.8	178	5.3	0.0	25.0	0.0	25.0	25.0	25.0	3,372	4	38
6-14	4.3	538	31.3	50.0	0.0	0.0	25.0	25.0	0.0	1,717	4	32
15-20	2.7	201	12.5	17.4	31.5	10.9	20.7	17.4	2.2	1,614	92	964
21-44	2.6	182	13.5	21.2	29.5	12.3	22.1	11.4	3.4	1,348	8,425	87,105
45-64	4.1	225	16.1	18.4	16.9	10.4	25.8	20.2	8.4	1,400	8,834	89,751
65-74	4.2	182	18.7	17.4	16.9	10.6	24.7	21.0	9.5	969	8,379	81,675
75-84	4.9	189	14.3	11.1	12.9	10.0	28.1	26.6	11.3	1,319	9,158	84,885
85 and older	5.1	172	9.6	6.0	11.0	9.7	33.0	29.1	11.2	1,798	9,784	86,410
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Basis of Eligibility												
Aged	4.9	184	12.8	11.3	12.7	9.7	28.8	26.4	11.1	1,438	25,207	230,189
Disabled	3.4	199	15.3	18.7	22.9	11.7	24.6	16.2	6.0	1,298	19,316	199,413
Adults	2.4	112	31.2	26.7	39.7	8.6	17.2	6.0	1.7	360	116	880
Children	2.3	146	5.5	34.1	19.5	7.3	24.4	14.6	0.0	2,651	41	378
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Gender												
Female	4.7	198	14.7	10.8	14.9	10.6	28.9	24.5	10.4	1,341	29,488	285,607
Male	3.3	176	12.3	21.9	21.7	10.5	23.1	17.0	5.7	1,434	15,192	145,253
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Race												
White	4.5	202	13.8	13.6	15.5	10.1	27.4	23.7	9.8	1,463	37,409	357,876
African American	3.0	142	13.7	19.4	24.4	12.6	25.1	14.1	4.4	1,034	4,862	49,029
Other/unknown	2.6	122	17.0	19.5	28.9	13.8	23.2	11.0	3.5	715	2,409	23,955
Use of Nursing Facilities												
Entire year	6.2	236	10.2	2.8	7.9	7.6	30.4	35.3	15.9	2,302	10,187	95,594
Part year	6.2	235	13.4	3.1	8.2	8.3	31.7	33.4	15.3	1,760	4,514	37,193
None	3.3	170	16.6	20.2	21.7	11.9	25.0	15.7	5.5	1,026	29,979	298,073
Maintenance Assistance Status												
Cash	3.3	166	20.1	11.9	25.8	14.0	27.5	15.9	5.0	823	14,620	155,266
Medically needy	5.1	217	11.9	13.3	11.3	8.8	27.9	27.0	11.7	1,828	26,883	244,630
Poverty related	1.2	70	35.6	49.2	25.8	8.0	11.8	4.0	1.4	196	2,073	19,365
Other/unknown	2.8	155	14.4	16.1	30.3	12.7	24.6	12.7	3.6	1,077	1,104	11,599

Source: Data for this table are from the MAX 1999 file for Kansas, released by CMS in 1/2004. This table was produced on 06/25/2004.

Table 13

Dual Eligible Beneficiaries

- a. Table 13 includes the beneficiaries represented by Cell G of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE 14
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC^{a, b, c}
 DUAL ELIGIBLE BENEFICIARIES, KANSAS, 1999

Beneficiary Characteristics	All Rx		Patented Brand-Name Drugs		Off-Patent Brand-Name Drugs		Generic Drugs	
	No. of Rx	Rx \$	No. of Rx	\$ per Rx	No. of Rx	\$ per Rx	No. of Rx	\$ per Rx
All	4.2	\$190	1.5	\$116	0.7	\$36	1.7	\$29
Age								
5 and younger	5.8	178	2.1	124	0.5	58	2.4	29
6-14	4.3	538	0.8	324	1.1	415	2.1	31
15-20	2.7	201	1.1	140	0.5	125	1.0	16
21-44	2.6	182	1.1	123	0.4	112	1.0	20
45-64	4.1	225	1.6	145	0.6	88	1.6	31
65-74	4.2	182	1.6	110	0.7	69	1.7	30
75-84	4.9	189	1.7	109	0.9	63	2.0	33
85 and older	5.1	172	1.6	92	1.0	59	2.3	34
Unknown	0.0	0	0.0	0	0.0	0	0.0	0
Basis of Eligibility								
Aged	4.9	184	1.7	104	0.9	63	2.1	33
Disabled	3.4	199	1.4	130	0.5	94	1.4	25
Adults	2.4	112	0.9	71	0.4	79	1.1	15
Children	2.3	146	1.0	106	0.3	102	0.9	14
Unknown	0.0	0	0.0	0	0.0	0	0.0	0
Gender								
Female	4.7	198	1.7	119	0.8	71	1.9	31
Male	3.3	176	1.2	109	0.6	92	1.3	25
Unknown	0.0	0	0.0	0	0.0	0	0.0	0
Race								
White	4.5	202	1.6	122	0.8	76	1.9	31
African American	3.0	142	1.1	88	0.5	81	1.2	21
Other/unknown	2.6	122	1.1	77	0.4	73	1.0	16
Use of Nursing Facilities								
Entire year	6.2	236	2.0	131	1.2	67	2.7	43
Part year	6.2	235	2.1	139	1.1	65	2.6	42
None	3.3	170	1.3	108	0.5	83	1.3	23
Maintenance Assistance Status								
Cash	3.3	166	1.3	105	0.5	82	1.3	23
Medically needy	5.1	217	1.8	129	0.9	73	2.1	35
Poverty related	1.2	70	0.5	44	0.2	94	0.5	9
Other/unknown	2.8	155	1.2	101	0.5	87	1.0	18

Source: Data for this table are from the MAX 1999 file for Kansas, released by CMS in 1/2004. This table was produced on 06/25/2004.

a. Table 14 includes the beneficiaries represented by Cell G of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

Table 14

Dual Eligible Beneficiaries

c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Kansas, 5.2 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all combined. For information about this classification method, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE 15

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d}
 DUAL ELIGIBLE BENEFICIARIES, KANSAS, 1999

Therapeutic Category	No. of Rx per Bene Mo among Users			\$ per Bene Mo among Users			\$ per Rx			Users							
	Total	Patented Brand-Name	Off-Patent Brand-Name	Total	Patented Brand-Name	Off-Patent Brand-Name	Total	Patented Brand-Name	Off-Patent Brand-Name	Total No. of Rx	Total Rx \$	No. Dual Benes	As % of Bene Mos				
														Generic	Generic	Generic	Generic
Anti-infective Agents	0.4	0.2	0.0	0.2	\$18	\$16	\$0	\$2	\$51	\$84	\$61	\$14	94,507	\$4,822,117	25,598	57.3 %	261,857
Biologics	0.6	0.0	0.3	0.2	####	0	811	####	3854	0	2,434	5,984	20	77,083	3	0.0	36
Antineoplastic Agents	0.6	0.2	0.2	0.2	83	53	21	9	148	274	131	44	7,260	1,077,635	1,377	3.1	13,011
Endocrine/Metabolic Drugs	0.9	0.4	0.2	0.3	27	19	3	4	29	47	17	13	165,632	4,801,991	17,643	39.5	179,198
Cardiovascular Agents	1.6	0.5	0.4	0.7	48	24	15	10	30	50	37	13	395,488	11,851,294	24,874	55.7	246,611
Respiratory Agents	0.8	0.4	0.0	0.4	32	24	0	8	39	55	31	22	120,356	4,732,683	14,339	32.1	147,100
Gastrointestinal Agents	0.8	0.3	0.1	0.3	52	34	11	7	67	103	78	23	121,956	8,195,368	15,666	35.1	158,613
Genitourinary Agents	0.5	0.3	0.0	0.2	21	16	0	5	40	55	30	21	33,790	1,346,076	6,325	14.2	64,436
CNS Drugs	1.3	0.7	0.2	0.4	98	69	23	6	78	102	102	18	264,027	20,530,715	20,847	46.7	209,430
Stimulants/Anti-obesity/Anorexia	0.6	0.1	0.1	0.5	23	5	5	13	35	51	56	28	2,586	91,786	400	0.9	3,981
Miscellaneous Psychological/Neurological Agents	0.6	0.5	0.0	0.0	60	57	2	1	109	117	107	28	10,011	1,089,541	1,880	4.2	18,195
Analgesics and Anesthetics	0.8	0.2	0.1	0.5	33	19	6	8	39	82	72	15	172,300	6,790,178	20,424	45.7	207,313
Neuromuscular Agents	1.1	0.4	0.2	0.5	52	32	8	12	48	87	45	22	133,395	6,441,840	11,995	26.8	123,965
Nutritional Products	0.7	0.0	0.2	0.5	14	0	7	7	20	23	28	15	66,249	1,293,647	9,545	21.4	93,487
Hematological Agents	0.9	0.1	0.4	0.4	33	14	11	8	39	154	28	23	49,767	1,950,086	5,957	13.3	58,402
Topical Products	0.4	0.2	0.1	0.2	13	7	3	2	30	43	35	14	69,023	2,051,919	15,927	35.6	164,127
Miscellaneous Products	0.4	0.1	0.1	0.2	61	38	17	6	164	258	281	35	5,290	868,308	1,405	3.1	14,338
Unknown Therapeutic Category	0.6	0.0	0.0	0.0	24	0	0	0	41	0	0	0	98,422	4,043,796	16,714	37.4	170,777
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	1,810,079	82,056,063	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 1999 file for Kansas, released by CMS in 1/2004. This table was produced on 06/25/2004.

- a. Table 15 includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 1999. A beneficiary who used drugs from two or more categories was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).
- d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Kansas, 5.2 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).
- Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE 16

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP^{a, b, c}
 DUAL ELIGIBLE BENEFICIARIES, KANSAS, 1999

Top 10 Drug Groups	Users			Among Users		
	Total Medicaid Rx \$	No.	As % of Dual Benes	No. of Bene Mos	No. of Rx per Bene Mo	Rx \$ per Bene Mo
ANTIPSYCHOTICS	\$10,937,034	11,471	25.7 %	121,015	0.8	\$117
ANTIDEPRESSANTS	6,802,787	18,156	40.6	190,980	0.6	56
ULCER DRUGS	6,348,425	14,334	32.1	151,506	0.5	77
ANTICONVULSANT	4,666,752	9,321	20.9	100,402	0.8	56
ANTIDIABETIC	3,162,794	10,004	22.4	105,670	0.7	41
ANTIHYPERTENSIVE	3,087,054	12,593	28.2	131,700	0.6	37
ANALGESICS - Narcotic	3,007,568	19,618	43.9	207,367	0.5	32
ANALGESICS - ANTI-INFLAMMATORY	2,923,964	12,823	28.7	139,933	0.4	53
ANTIASTHMATIC	2,689,135	13,254	29.7	139,862	0.5	37
CALCIUM BLOCKERS	2,646,310	7,395	16.6	77,699	0.7	51

Source: Data for this table are from the MAX 1999 file for Kansas, released by CMS in 1/2004. This table was produced on 06/25/2004.

a. Table 16 includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 1999. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 1999. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE 16A
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED
 AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BOE, AND AGE^{a, b, c}
 DUAL ELIGIBLE BENEFICIARIES, KANSAS, 1999

Beneficiary Characteristics	All Top 10 Drug Groups				ANTIPSYCHOTICS				ANTIDEPRESSANTS			
	No. of Rx	Rx \$	No. of Users	Users as % of Dual Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of Dual Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$
All	818,051	\$46,271,823	11,471	25.7 %	121,015	0.8	\$90	18,156	40.6 %	190,980	0.6	\$36
Female	580,853	31,018,814	6,976	23.7	73,466	0.7	76	13,297	45.1	140,498	0.6	35
Disabled	219,387	13,898,706	3,015	29.1	33,886	0.8	99	5,670	54.8	63,406	0.6	36
5 and younger	16	220	0	0.0	0	0.0	0	0	0.0	0	0.0	0
6-14	9	510	0	0.0	0	0.0	0	0	0.0	0	0.0	0
15-20	488	37,094	10	35.7	120	1.0	130	13	46.4	156	0.5	32
21-44	65,966	4,735,666	1,382	36.9	15,541	0.7	102	2,171	58.0	24,301	0.5	37
45-64	121,470	7,514,836	1,430	28.5	16,099	0.8	100	2,983	59.5	33,260	0.6	36
65-74	28,608	1,473,150	180	13.4	1,994	0.7	76	462	34.3	5,265	0.5	27
75-84	2,345	114,525	13	7.7	132	0.7	54	35	20.7	368	0.5	26
85 and older	485	22,705	0	0.0	0	0.0	0	6	14.3	56	0.8	63
Other Eligibles	361,466	17,120,108	3,961	20.7	39,580	0.7	56	7,627	39.8	77,092	0.7	35
5 and younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
6-14	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
15-20	109	5,370	4	40.0	38	0.3	15	5	50.0	55	0.5	39
21-44	724	56,907	12	15.6	139	0.4	111	31	40.3	315	0.4	29
45-64	207	9,435	0	0.0	0	0.0	0	5	45.5	51	0.6	49
65-74	91,918	4,669,858	891	20.8	9,451	0.8	76	1,684	39.2	18,002	0.7	33
75-84	134,882	6,470,851	1,431	21.3	14,283	0.7	58	2,719	40.6	27,447	0.7	35
85 and older	133,626	5,907,687	1,623	20.2	15,669	0.6	42	3,183	39.6	31,222	0.7	36
Male	237,198	15,253,009	4,495	29.6	47,549	0.9	113	4,859	32.0	50,482	0.6	37
Disabled	138,588	10,535,312	3,047	34.0	33,769	0.9	135	2,773	30.9	30,583	0.6	37
5 and younger	25	524	0	0.0	0	0.0	0	0	0.0	0	0.0	0
6-14	17	412	0	0.0	0	0.0	0	0	0.0	0	0.0	0
15-20	424	25,072	14	34.1	158	0.5	63	12	29.3	134	0.4	21
21-44	60,498	5,194,634	1,755	38.4	19,459	0.9	132	1,467	32.1	16,289	0.6	38
45-64	68,300	4,846,805	1,206	31.8	13,333	1.0	144	1,172	30.9	12,792	0.6	37
65-74	8,593	431,233	66	13.3	751	0.7	73	115	23.1	1,287	0.5	27
75-84	689	34,618	6	10.3	68	0.8	56	7	12.1	81	0.5	26
85 and older	42	2,014	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	98,610	4,717,697	1,448	23.3	13,780	0.7	58	2,086	33.5	19,899	0.7	36
5 and younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
6-14	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
15-20	166	9,235	2	15.4	24	1.3	76	1	7.7	12	1.0	252
21-44	421	23,662	10	27.0	109	0.5	63	13	35.1	141	0.4	27
45-64	112	7,498	1	8.3	8	0.1	9	5	41.7	56	0.3	28
65-74	35,470	1,864,769	492	21.9	5,089	0.8	78	632	28.2	6,446	0.7	37
75-84	36,838	1,725,240	518	23.3	4,854	0.7	55	778	35.0	7,351	0.7	36
85 and older	25,603	1,087,293	425	25.2	3,696	0.6	34	657	38.9	5,893	0.7	35
Unknown	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 1999 file for Kansas, released by CMS in 1/2004. This table was produced on 06/25/2004.

a. Table 16A includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 1999. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 1999. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mdmb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE 16B
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS
 SEPARATELY, BY SEX, BOE, AND AGE^{a, b, c}
 DUAL ELIGIBLE BENEFICIARIES, KANSAS, 1999

Beneficiary Characteristics	ULCER DRUGS					ANTICONVULSANT					ANTIDIABETIC				
	No. of Users	Users as % of Dual Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of Dual Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of Dual Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$
All	14,334	32.1 %	151,506	0.5	\$42	9,321	20.9 %	100,402	0.8	\$47	10,004	22.4 %	105,670	0.7	\$30
Female	10,514	35.7	111,448	0.5	42	5,629	19.1	60,442	0.8	43	7,440	25.2	78,920	0.7	30
Disabled	3,639	35.2	40,761	0.4	40	3,142	30.4	35,177	0.8	50	2,578	24.9	28,735	0.7	33
5 and younger	1	50.0	8	1.0	17	0	0.0	0	0.0	0	0	0.0	0	0.0	0
6-14	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
15-20	7	25.0	82	0.3	37	12	42.9	144	0.6	35	1	3.6	11	0.4	5
21-44	975	26.0	10,995	0.4	37	1,460	39.0	16,298	0.8	53	400	10.7	4,487	0.7	31
45-64	2,032	40.5	22,618	0.5	41	1,501	29.9	16,833	0.8	50	1,542	30.8	17,119	0.7	35
65-74	564	41.9	6,394	0.5	40	158	11.7	1,789	0.7	29	586	43.6	6,550	0.6	30
75-84	47	27.8	530	0.4	40	10	5.9	101	0.5	25	45	26.6	524	0.6	30
85 and older	13	31.0	134	0.4	21	1	2.4	12	0.3	4	4	9.5	44	0.8	34
Other Eligibles	6,875	35.9	70,687	0.6	43	2,487	13.0	25,265	0.8	34	4,862	25.4	50,185	0.8	29
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
6-14	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
15-20	1	10.0	12	0.3	9	4	40.0	40	0.4	12	1	10.0	12	1.2	85
21-44	16	20.8	165	0.5	24	19	24.7	197	0.6	71	12	15.6	127	0.9	50
45-64	10	90.9	103	0.2	27	2	18.2	24	0.6	16	2	18.2	24	0.7	22
65-74	1,523	35.5	16,495	0.5	41	778	18.1	8,248	0.9	41	1,507	35.1	16,119	0.7	32
75-84	2,517	37.5	26,145	0.6	43	939	14.0	9,444	0.8	31	2,032	30.3	21,073	0.8	29
85 and older	2,808	34.9	27,767	0.7	45	745	9.3	7,312	0.8	28	1,308	16.3	12,830	0.8	24
Male	3,820	25.1	40,058	0.5	42	3,692	24.3	39,960	0.9	52	2,564	16.9	26,750	0.7	29
Disabled	1,941	21.6	21,693	0.5	41	2,700	30.1	30,160	0.9	57	1,204	13.4	13,252	0.7	32
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
6-14	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
15-20	10	24.4	120	0.3	21	10	24.4	112	0.8	39	0	0.0	0	0.0	0
21-44	790	17.3	8,882	0.5	41	1,441	31.6	16,162	0.8	58	303	6.6	3,366	0.7	31
45-64	946	24.9	10,478	0.5	42	1,187	31.3	13,188	0.9	57	765	20.1	8,332	0.7	34
65-74	177	35.5	2,000	0.4	35	56	11.2	626	0.8	36	124	24.9	1,412	0.7	31
75-84	17	29.3	201	0.3	25	5	8.6	60	1.0	75	12	20.7	142	0.5	16
85 and older	1	14.3	12	0.8	32	1	14.3	12	0.2	5	0	0.0	0	0.0	0
Other Eligibles	1,879	30.2	18,365	0.6	43	992	15.9	9,800	0.8	34	1,360	21.9	13,498	0.7	26
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
6-14	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
15-20	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
21-44	10	27.0	117	0.3	22	10	27.0	87	1.1	47	1	7.7	12	0.6	17
45-64	2	16.7	24	0.6	48	0	0.0	0	0.0	33	2	5.4	24	0.8	20
65-74	561	25.0	5,847	0.6	42	427	19.0	4,432	0.9	39	502	22.4	5,064	0.7	29
75-84	704	31.6	6,938	0.6	43	332	14.9	3,239	0.8	30	534	24.0	5,296	0.7	26
85 and older	602	35.7	5,439	0.7	46	218	12.9	1,982	0.8	29	319	18.9	3,078	0.8	23
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Dual Eligible Beneficiaries

Table 16B

Source: Data for this table are from the MAX 1999 file for Kansas, released by CMS in 1/2004. This table was produced on 06/25/2004.

a. Table 16B includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 1999. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 1999. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE 16C
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS
 SEPARATELY, BY SEX, BOE, AND AGE^{a, b, c}
 DUAL ELIGIBLE BENEFICIARIES, KANSAS, 1999

Beneficiary Characteristics	ANTIHYPERTENSIVE					ANALGESICS - Narcotic					ANALGESICS - ANTI-INFLAMMATORY				
	No. of Users	Users as % of Dual Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of Dual Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of Dual Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$
All	12,593	28.2 %	131,700	0.6	\$23	19,618	43.9 %	207,367	0.5	\$15	12,823	28.7 %	139,933	0.4	\$21
Female	9,164	31.1	96,025	0.6	23	14,691	49.8	155,650	0.5	15	9,683	32.8	105,694	0.4	22
Disabled	2,470	23.9	27,558	0.6	23	6,147	59.4	68,769	0.4	15	4,168	40.3	47,145	0.3	21
5 and younger	1	50.0	8	1.0	11	0	0.0	0	0.0	0	0	0.0	0	0.0	0
6-14	1	100.0	12	0.5	23	0	0.0	0	0.0	0	0	0.0	0	0.0	0
15-20	9	32.1	104	0.7	28	15	53.6	176	0.2	4	6	21.4	72	0.1	3
21-44	396	10.6	4,431	0.5	20	2,091	55.8	23,560	0.4	13	1,244	33.2	14,141	0.3	14
45-64	1,399	27.9	15,532	0.6	23	3,140	62.6	34,802	0.5	17	2,172	43.3	24,392	0.4	24
65-74	594	44.2	6,728	0.6	24	806	59.9	9,158	0.4	11	667	49.6	7,671	0.4	21
75-84	57	33.7	615	0.6	24	83	49.1	957	0.5	6	63	37.3	697	0.3	22
85 and older	13	31.0	128	0.7	24	12	28.6	116	0.3	5	16	38.1	172	0.4	23
Other Eligibles	6,694	35.0	68,467	0.7	24	8,544	44.6	86,881	0.5	15	5,515	28.8	58,549	0.4	24
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
6-14	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
15-20	1	10.0	12	1.1	24	3	30.0	31	0.2	7	1	10.0	12	0.6	12
21-44	4	5.2	47	0.1	9	30	39.0	278	0.3	11	20	26.0	215	0.3	9
45-64	2	18.2	11	0.4	9	13	118.2	122	0.4	10	4	36.4	45	0.3	5
65-74	1,656	38.6	17,664	0.6	23	2,029	47.3	21,783	0.5	14	1,462	34.1	16,211	0.4	22
75-84	2,532	37.8	26,157	0.7	24	3,019	45.0	30,998	0.5	15	2,092	31.2	22,248	0.5	25
85 and older	2,499	31.1	24,576	0.7	24	3,450	42.9	33,669	0.5	16	1,936	24.1	19,818	0.5	23
Male	3,429	22.6	35,675	0.6	24	4,927	32.4	51,717	0.4	14	3,140	20.7	34,239	0.4	17
Disabled	1,529	17.0	16,960	0.6	23	2,919	32.5	32,299	0.4	14	1,841	20.5	20,763	0.3	14
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	50.0	12	0.8	9
6-14	1	100.0	12	0.8	7	1	100.0	12	0.1	2	0	0.0	0	0.0	0
15-20	13	31.7	146	0.5	12	16	39.0	179	0.3	6	8	19.5	95	0.1	2
21-44	455	10.0	5,004	0.5	22	1,409	30.9	15,615	0.4	15	792	17.3	8,941	0.3	11
45-64	840	22.1	9,309	0.6	23	1,267	33.4	13,923	0.5	15	862	22.7	9,641	0.4	18
65-74	186	37.3	2,094	0.5	23	209	42.0	2,372	0.4	7	161	32.3	1,870	0.3	17
75-84	28	48.3	327	0.5	21	16	27.6	186	0.3	3	17	29.3	204	0.3	16
85 and older	6	85.7	68	0.4	19	1	14.3	12	0.1	0	0	0.0	0	0.0	0
Other Eligibles	1,900	30.5	18,715	0.7	25	2,008	32.3	19,418	0.4	13	1,299	20.9	13,476	0.4	20
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
6-14	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
15-20	4	30.8	38	0.8	19	0	0.0	0	0.0	0	2	15.4	24	0.5	18
21-44	5	13.5	49	0.5	34	17	45.9	192	0.6	9	15	40.5	162	0.3	21
45-64	2	16.7	24	1.0	82	5	41.7	50	0.4	14	6	50.0	59	0.3	9
65-74	677	30.2	7,083	0.6	24	684	30.5	6,895	0.4	14	447	19.9	4,852	0.4	20
75-84	716	32.2	7,065	0.7	26	725	32.6	7,157	0.4	12	485	21.8	5,086	0.4	19
85 and older	496	29.4	4,456	0.7	24	577	34.2	5,124	0.4	11	344	20.4	3,293	0.5	21
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Table 16C

Dual Eligible Beneficiaries

Source: Data for this table are from the MAX 1999 file for Kansas, released by CMS in 1/2004. This table was produced on 06/25/2004.

a. Table 16C includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 1999. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 1999. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE 16D
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS
 SEPARATELY, BY SEX, BOE, AND AGE^{a, b, c}
 DUAL ELIGIBLE BENEFICIARIES, KANSAS, 1999

Beneficiary Characteristics	ANTIASTHMATIC				CALCIUM BLOCKERS				Mean Rx \$	Mean No. of Rx	Users as % of Dual Benes	No. of Users	No. of Bene Mos among Users	Mean Rx \$	Mean No. of Rx	Users as % of Dual Benes	No. of Bene Mos among Users	No. of Bene Mos
	No. of Users	Users as % of Dual Benes	No. of Bene Mos among Users	Mean Rx \$	Mean No. of Rx	Users as % of Dual Benes	No. of Users	No. of Bene Mos among Users										
All	13,254	29.7 %	139,862	0.5	\$19	7,395	16.6 %	77,699	0.7	\$34	44,680	430,860						
Female	9,379	31.8	99,893	0.5	19	5,651	19.2	59,386	0.7	34	29,488	285,607						
Disabled	3,948	38.2	44,232	0.4	17	1,501	14.5	16,847	0.6	34	10,345	108,057						
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	2	14						
6-14	0	0.0	0	0.0	0	1	100.0	12	0.3	20	1	12						
15-20	8	28.6	93	0.5	23	4	14.3	47	0.7	55	28	320						
21-44	1,068	28.5	12,121	0.4	14	208	5.6	2,338	0.5	32	3,745	39,233						
45-64	2,219	44.3	24,817	0.5	19	859	17.1	9,611	0.6	34	5,013	51,673						
65-74	600	44.6	6,637	0.4	17	369	27.4	4,173	0.6	36	1,345	14,606						
75-84	37	21.9	390	0.4	11	50	29.6	550	0.5	32	169	1,782						
85 and older	16	38.1	174	0.5	17	10	23.8	116	0.6	32	42	417						
Other Eligibles	5,431	28.4	55,661	0.5	20	4,150	21.7	42,539	0.7	34	19,143	177,550						
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0						
6-14	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	2						
15-20	3	30.0	36	0.2	11	0	0.0	0	0.0	0	10	89						
21-44	18	23.4	191	0.3	8	5	6.5	60	0.3	16	77	606						
45-64	7	63.6	84	0.4	11	2	18.2	18	0.7	47	11	109						
65-74	1,629	38.0	17,421	0.6	23	963	22.4	10,279	0.7	35	4,291	41,493						
75-84	2,044	30.5	20,809	0.6	21	1,621	24.2	16,820	0.7	35	6,705	63,208						
85 and older	1,730	21.5	17,120	0.5	16	1,559	19.4	15,362	0.8	34	8,048	72,043						
Male	3,875	25.5	39,969	0.6	21	1,744	11.5	18,313	0.6	33	15,192	145,253						
Disabled	1,779	19.8	19,526	0.5	19	808	9.0	8,953	0.6	35	8,971	91,356						
5 and younger	3	150.0	36	0.4	12	0	0.0	0	0.0	0	2	24						
6-14	1	100.0	12	0.5	26	0	0.0	0	0.0	0	1	12						
15-20	5	12.2	60	0.1	3	7	17.1	74	0.6	31	41	439						
21-44	562	12.3	6,323	0.4	15	229	5.0	2,541	0.5	35	4,566	46,977						
45-64	949	25.0	10,273	0.5	20	442	11.6	4,854	0.6	35	3,798	37,882						
65-74	235	47.2	2,538	0.6	24	120	24.1	1,368	0.6	36	498	5,314						
75-84	23	39.7	272	0.3	13	9	15.5	106	0.5	26	58	626						
85 and older	1	14.3	12	0.1	0	1	14.3	10	0.2	25	7	82						
Other Eligibles	2,096	33.7	20,443	0.6	22	936	15.0	9,360	0.7	32	6,221	53,897						
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0						
6-14	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	6						
15-20	0	0.0	0	0.0	0	1	7.7	2	1.0	64	13	116						
21-44	3	8.1	36	0.2	2	1	2.7	1	1.0	63	37	289						
45-64	0	0.0	0	0.0	0	2	16.7	24	0.5	21	12	87						
65-74	768	34.2	7,756	0.6	23	324	14.4	3,399	0.6	36	2,245	20,262						
75-84	799	35.9	7,699	0.7	23	396	17.8	3,905	0.7	30	2,226	19,269						
85 and older	526	31.2	4,952	0.6	19	212	12.6	2,029	0.7	28	1,687	13,868						
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0						

Table 16D

Dual Eligible Beneficiaries

Source: Data for this table are from the MAX 1999 file for Kansas, released by CMS in 1/2004. This table was produced on 06/25/2004.

a. Table 16D includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 1999. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 1999. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE 17
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,
 BY BENEFICIARY CHARACTERISTIC^{a, b}
 DUAL ELIGIBLE BENEFICIARIES, KANSAS, 1999

Beneficiary Characteristics	Rx \$ per Bene Mo	No. of Rx per Bene Mo	No. of All-Year NF Residents	Bene Mos among All-Year NF Residents
All	\$236	6.2	10,187	95,594
Age				
0-64	439	7.1	772	8,123
65-74	288	6.9	1,132	11,043
75-84	243	6.5	2,917	27,160
85 and older	187	5.7	5,366	49,268
Unknown	0	0.0	0	0
Gender				
Female	225	6.2	7,660	72,140
Male	271	6.0	2,527	23,454
Unknown	0	0.0	0	0
Race				
White	236	6.2	9,509	88,975
African American	230	5.3	500	4,868
Other/unknown	229	5.9	178	1,751
Basis of Eligibility				
Aged	217	6.1	9,360	86,903
Disabled	429	7.0	827	8,691
Adults	0	0.0	0	0
Children	0	0.0	0	0
Unknown	0	0.0	0	0

Source: Data for this table are from the MAX 1999 file for Kansas, released by CMS in 1/2004. This table was produced on 06/25/2004.

a. Table 17 includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their 1999 Medicaid enrollment. A total of 4,514 beneficiaries who were in nursing facilities for part of their enrollment and their 37,193 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE 18

**MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,
BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d, e}
DUAL ELIGIBLE BENEFICIARIES, KANSAS, 1999**

Therapeutic Category	No. of Rx per Bene Mo among Users			\$ per Bene Mo among Users			\$ per Rx			Users						
	Total	Patented	Off-Patent	Total	Patented	Off-Patent	Total	Patented	Off-Patent	Total # of Rx	Total Rx \$	No.	As % of Dual All-Year NF Residents	No. of Bene Mos		
		Brand-Name	Generic		Brand-Name	Generic		Brand-Name	Generic							
Anti-infective Agents	0.4	0.2	0.0	0.2	\$12	\$0	\$2	\$40	\$63	\$41	\$12	26,077	\$1,040,130	7,243	71.1 %	71,270
Biologics	0.0	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0.0	0
Antineoplastic Agents	0.7	0.2	0.2	0.3	71	26	34	106	167	136	43	2,682	283,792	454	4.5	3,992
Endocrine/Metabolic Drugs	1.2	0.4	0.3	0.5	27	17	4	22	41	14	11	49,327	1,098,862	4,290	42.1	41,456
Cardiovascular Agents	2.0	0.4	0.5	1.0	44	16	15	22	39	29	12	133,123	2,955,085	7,137	70.1	67,913
Respiratory Agents	0.8	0.3	0.0	0.5	27	15	0	32	48	26	23	30,797	993,328	3,740	36.7	36,704
Gastrointestinal Agents	1.0	0.4	0.2	0.4	55	33	13	57	87	71	23	40,106	2,268,192	4,242	41.6	41,177
Genitourinary Agents	0.6	0.3	0.0	0.3	24	17	0	38	54	33	21	13,479	511,082	2,098	20.6	20,951
CNS Drugs	1.6	0.9	0.3	0.4	110	78	26	70	87	92	15	94,233	6,621,417	6,228	61.1	60,204
Stimulants/Anti-obesity/Anorexia	0.8	0.1	0.1	0.7	18	3	1	22	40	28	19	835	17,972	109	1.1	1,022
Miscellaneous Psychological/Neurological Agents	0.9	0.9	0.0	0.0	92	92	0	105	107	87	28	4,556	477,059	566	5.6	5,161
Analgesics and Anesthetics	0.9	0.3	0.1	0.6	33	20	5	36	74	56	14	42,113	1,520,377	4,770	46.8	45,522
Neuromuscular Agents	1.3	0.4	0.3	0.7	56	27	14	42	70	49	23	40,199	1,680,392	3,006	29.5	29,796
Nutritional Products	0.9	0.0	0.3	0.6	16	0	7	18	25	25	14	29,267	520,872	3,370	33.1	32,772
Hematological Agents	1.2	0.1	0.6	0.5	37	11	14	31	124	23	23	19,496	601,865	1,705	16.7	16,113
Topical Products	0.5	0.2	0.1	0.2	13	7	4	26	37	34	13	26,195	691,452	5,274	51.8	52,813
Miscellaneous Products	0.3	0.1	0.0	0.2	10	3	1	33	34	108	29	1,022	33,224	352	3.5	3,493
Unknown Therapeutic Category	0.7	0.0	0.0	0.0	25	0	0	34	0	0	0	36,892	1,238,322	5,078	49.8	50,100
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	590,399	22,553,423	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 1999 file for Kansas, released by CMS in 1/2004. This table was produced on 06/25/2004.

a. Table 18 includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 1999. A total of 4,514 beneficiaries who were in nursing facilities for part of their enrollment and their 37,193 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 1999. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

In Kansas, 5.2 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

Table 18

Dual Eligible Beneficiaries

Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

APPENDIX TABLE A.3
 CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY^{a, b}
 DUAL ELIGIBLE BENEFICIARIES, KANSAS, 1999

Beneficiary Characteristics	No. of Benes					No. of Bene Mos					
	All	Aged	Disabled	Adults	Children	All	Aged	Disabled	Adults	Children	Unknown
All	47,221	26,989	20,060	128	44	485,390	266,967	216,996	1,004	423	0
Age											
5 and younger	4	0	4	0	0	45	0	45	0	0	0
6-14	4	0	2	0	2	32	0	24	0	8	0
15-20	95	3	69	1	22	1,024	31	777	5	211	0
21-44	8,716	1	8,592	103	20	94,093	12	93,078	799	204	0
45-64	9,230	3	9,205	22	0	98,785	36	98,562	187	0	0
65-74	8,824	6,924	1,898	2	0	91,489	70,174	21,302	13	0	0
75-84	9,789	9,548	241	0	0	98,408	95,741	2,667	0	0	0
85 and older	10,559	10,510	49	0	0	101,514	100,973	541	0	0	0
Unknown	0	0	0	0	0	0	0	0	0	0	0
Gender											
Female	31,196	20,385	10,710	81	20	323,019	205,165	117,022	648	184	0
Male	16,025	6,604	9,350	47	24	162,371	61,802	99,974	356	239	0
Unknown	0	0	0	0	0	0	0	0	0	0	0
Race											
White	39,656	23,378	16,143	96	39	405,792	229,696	174,964	760	372	0
African American	5,051	2,145	2,882	21	3	53,225	22,034	31,003	161	27	0
Other/unknown	2,514	1,466	1,035	11	2	26,373	15,237	11,029	83	24	0
Use of Nursing Facilities											
All year	10,955	10,096	859	0	0	111,965	102,377	9,588	0	0	0
Part year	4,861	4,383	478	0	0	43,542	38,569	4,973	0	0	0
None	31,405	12,510	18,723	128	44	329,883	126,021	202,435	1,004	423	0
Maintenance Assistance Status											
Cash	15,123	4,865	10,190	67	1	167,885	54,121	113,221	541	2	0
Medically needy	28,785	21,113	7,634	2	36	283,283	203,081	79,818	24	360	0
Poverty related	2,169	852	1,284	31	2	21,688	8,311	13,160	203	14	0
Other/unknown	1,144	159	952	28	5	12,534	1,454	10,797	236	47	0
Dual Status^c											
Full dual, all year	43,499	25,383	17,956	120	40	445,893	250,100	194,508	910	375	0
Full dual, part year	3,722	1,606	2,104	8	4	39,497	16,867	22,488	94	48	0
Managed Care Status											
FFS all year	38,815	21,294	17,379	104	38	396,931	207,995	187,748	824	364	0
FFS part year, with Rx claims	5,180	3,576	1,592	10	2	57,873	39,456	18,298	95	24	0
FFS part year, no Rx claims	685	337	345	2	1	6,913	3,251	3,634	23	5	0
MC all year, with Rx claims	2,123	1,566	549	5	3	20,868	14,886	5,914	38	30	0
MC all year, no Rx claims	418	216	195	7	0	2,805	1,379	1,402	24	0	0

Source: Data for this table are from the MAX 1999 file for Kansas, released by CMS in 1/2004. This table was produced on 06/25/2004.

a. Table A.3 includes the beneficiaries represented by Cell F of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. The "Full dual, all year" group contains beneficiaries who had Medicare as well as Medicaid pharmacy benefits during all months of Medicaid enrollment in 1999. The "Full dual, part year" group contains beneficiaries who had such benefits for some, but not all, months of their enrollment. Refer to footnote g of Table 1 for more information about how we determined dual eligibility status.

Bene Mo(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.4
 MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS
 DUAL ELIGIBLE BENEFICIARIES, KANSAS, 1999

Beneficiary Characteristics	Benes and					
	Bene Mos in Cell F of Table 1		Included in Cell G of Table 1		Excluded from Cell G of Table 1	
	No. of Benes	No. of Bene Mos	No. of Benes	No. of Bene Mos	No. of Benes	No. of Bene Mos
All	47,221	485,390	44,680	430,860	2,541	54,530
FFS all year	38,815	396,931	38,815	396,931	0	0
FFS part year, with Rx claims	5,180	57,873	5,180	30,323	0	27,550
FFS part year, with no Rx claims	685	6,913	685	3,606	0	3,307
MC all year, with Rx claims	2,123	20,868	0	0	2,123	20,868
MC all year, with no Rx claims	418	2,805	0	0	418	2,805

Source: Data for this table are from the MAX 1999 file for Kansas, released by CMS in 1/2004. This table was produced on 06/25/2004.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

—
icy
ent
%

SUPPLEMENTAL TABLE 1D
 MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER^{a, b}
 KANSAS, 1999

Total Number of Dual Eligible Beneficiaries, Age 85+ 9,784
 Total Pharmacy Reimbursement for Dual Eligible Beneficiaries, Age 85+ \$14,882,798
 Mean Pharmacy Reimbursement per Dual Eligible Beneficiary, Age 85+ \$1,521

Annual Pharmacy Reimbursement per Beneficiary	Number of Beneficiaries	Percent of Dual Beneficiaries, Age 85+ 6.0 %	Pharmacy Reimbursement	Percent of Total Pharmacy Reimbursement
\$0	590		0	0.0 %
1-500	2,374	24.3	555,191	3.7
501-1,000	1,607	16.4	1,186,510	8.0
1,001-1,500	1,312	13.4	1,630,778	11.0
1,501-2,000	1,028	10.5	1,784,860	12.0
2,001-2,500	786	8.0	1,762,453	11.8
2,501-3,000	639	6.5	1,751,731	11.8
3,001-3,500	459	4.7	1,488,509	10.0
3,501-4,000	314	3.2	1,172,936	7.9
4,001-4,500	223	2.3	945,208	6.4
4,501-5,000	146	1.5	691,506	4.6
5,001-5,500	106	1.1	553,205	3.7
5,501-6,000	71	0.7	406,761	2.7
6,001-6,500	39	0.4	243,508	1.6
6,501-7,000	33	0.3	221,851	1.5
7,001-7,500	14	0.1	101,578	0.7
7,501-8,000	10	0.1	78,748	0.5
8,001-8,500	9	0.1	73,924	0.5
8,501-9,000	9	0.1	79,515	0.5
9,001-9,500	3	0.0	27,510	0.2
9,501-10,000	5	0.1	48,114	0.3
10,001+	7	0.1	78,402	0.5

Source: Data for this table are from the MAX 1999 file for Kansas, released by CMS in 1/2004. This table was produced on 10/26/2004.

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment in 1999.

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.